American Association for Cancer Research

SHERPA: Unknown

People

  1. Traina
    Traina
  2. Hudis
    Hudis
  3. Gucalp
    Gucalp
  4. Norton
    Norton
  5. Lake
    Lake
  6. Modi
    Modi
  7. Dang
    Dang
  8. D'Andrea-Carlino
    D'Andrea-Carlino
  9. Feigin
    Feigin
  10. Fornier
    Fornier

Groups

  1. Breast Medicine Service (55)
  2. Department of Medicine (55)
  3. Solid Tumor Oncology Division (55)
  4. Survivorship Research (55)
  5. Epidemiology and Biostatistics (21)
  6. Biostatistics Service (19)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (15)
  8. GSK Faculty (11)
  9. Department of Pathology and Laboratory Medicine (10)
  10. Population Sciences Research Program (9)
Search Within
  1. "Tiffany Traina"
Formats
  1. Meeting Abstract (44)
  2. Journal Article (11)
Groups
  1. Breast Medicine Service (55)
  2. Department of Medicine (55)
  3. Solid Tumor Oncology Division (55)
  4. Survivorship Research (55)
  5. Epidemiology and Biostatistics (21)
  6. Biostatistics Service (19)

More Groups

People
  1. Tiffany Traina (55)
  2. Clifford Hudis (28)
  3. Sujata Patil (19)
  4. Ayca Gucalp (18)
  5. Larry Norton (12)
  6. Diana Lake (9)

More People

Years
  1. 2024 (1)
  2. 2022 (2)
  3. 2021 (5)
  4. 2020 (5)
  5. 2018 (4)
  6. 2017 (3)

More Years

Publications
  1. Cancer Research (44)
  2. Clinical Cancer Research (11)

Results (55)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer
    Journal Article

    Tan, T. J.; Sammons, S.; Im, Y. H.; She, L.; Mundy, K.; Bigelow, R.; Traina, T. A.; Anders, C.; Yeong, J.; Renzulli, E.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple negative breast cancer: A feasibility study
    Meeting Abstract

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer
    Journal Article

    Chakraborty, G.; Nandakumar, S.; Hirani, R.; Nguyen, B.; Stopsack, K. H.; Kreitzer, C.; Rajanala, S. H.; Ghale, R.; Mazzu, Y. Z.; Pillarsetty, N. V. K.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • RASAL2 confers collateral MEK/EGFR dependency in chemoresistant triple-negative breast cancer
    Journal Article

    Koh, S. B.; Ross, K.; Isakoff, S. J.; Melkonjan, N.; He, L.; Matissek, K. J.; Schultz, A.; Mayer, E. L.; Traina, T. A.; Carey, L. A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Tenacity: A phase 2, multicenter, open-label, single-arm study of AL101 monotherapy in patients with notch-activated triple negative breast cancer
    Meeting Abstract

    Traina, T. A.; Cobain, E. F.; Evron, E.; Duksin, C.; Gordon, G.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)
    Meeting Abstract

    Krop, I.; Yonemori, K.; Takahashi, S.; Inoue, K.; Nakayama, T.; Iwata, H.; Toyama, T.; Yamamoto, Y.; Takahashi, M.; Osaki, A.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
    Meeting Abstract

    Hurvitz, S. A.; Tolaney, S. M.; Punie, K.; Loirat, D.; Oliveira, M.; Kalinsky, K.; Zelnak, A.; Aftimos, P.; Dalenc, F.; Sardesai, S.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer
    Meeting Abstract

    DieĢras, V.; Weaver, R.; Tolaney, S. M.; Bardia, A.; Punie, K.; Brufsky, A.; Rugo, H. S.; Kalinsky, K.; Traina, T.; Klein, L.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A randomized placebo controlled phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer
    Journal Article

    Krop, I.; Abramson, V.; Colleoni, M.; Traina, T.; Holmes, F.; Garcia-Estevez, L.; Hart, L.; Awada, A.; Zamagni, C.; Morris, P. G.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) during one year of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer
    Meeting Abstract

    Traina, T. A.; Jones, L. W.; Blinder, V.; Scott, J.; Boyle, L. A.; Arumov, A.; Alano, T.; Patil, S.; DeFusco, P.; Lamparella, N.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: